incretin.
2 articles · search the full text for this term
-
Dipeptidyl peptidase-IV (DPP-IV) Inhibitors – a promising oral anti-diabetic drug
Abstract: Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins i.e glucagon-like peptide1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Incretins augment the insulin release by a blood glucose-dependent mechanism. Generally DPP-IV enzyme is responsible for inactivating incretins and this enzyme inhibition will prolong and enhance the activity of GLP-1 and GIP. DPP-IV inhibitors increase post prandial insulin secretion, decreases glucagon secretion and seems to have beneficial effect on cardiovascular system, …
Published in Research and Reviews: A Journal of Pharmaceutical Science · Vol. 11, Issue 3, 2020 · pp. 1–6 Read article
-
Short Review on Diabetes Mellitus
Abstract: Diabetes mellitus is fastly growing health problem worldwide. Present article discussed about diabetes in general including its introduction, Pathophysiology, sign & symptoms and some of currently available treatments and possible newer approaches briefly. One of major problem associated with present antidiabetics drugs are they possessing variety of adverse effect which is ultimately diverting focus of researchers on newer approaches to treat both types of diabetes. In current review, we will …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 4, Issue 2, 2014 · pp. 15–24 Read article